Aardvark Therapeutics, Inc. (AARD)
NMS · Healthcare · Biotechnology
$5.13
+2.40%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$112.3M
Shares Outstanding
21.9M
Exchange
NMS
Currency
USD
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (17.7M) | (18.7M) | (22.5M) | (15.1M) |
| Net Income | (16.3M) | (17.6M) | (21.6M) | (14.4M) |
| Diluted EPS | $-0.75 | $-0.81 | $-0.99 | $-0.66 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (10.9M) | (6.7M) | (22.7M) | (62.7M) |
| Net Income | (13.6M) | (7.2M) | (20.6M) | (57.6M) |
| Diluted EPS | $-1.39 | $-0.56 | $-0.96 | $-2.93 |